Back to Resource Center

First-in-Human Trial of MIV-150 and Zinc Acetate Co-Formulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence and Pharmacodynamics

First-in-Human Trial of MIV-150 and Zinc Acetate Co-Formulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence and Pharmacodynamics

December 2016

Click to view Journal Article

Click for full info +

First-in-Human Trial of MIV-150 and Zinc Acetate Co-Formulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence and Pharmacodynamics

First-in-Human Trial of MIV-150 and Zinc Acetate Co-Formulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence and Pharmacodynamics
15 December 2016
click to view Journal Article
In this Journal Article:
Health Risk(s):

  • HIV
    • Product Type(s):

  • Microbicides
  • MPTs
    • Topic(s):

  • MPTs
  • Product Development
  • Product Trials


    • Full Info:


    Resource Type:

    Journal Article

    Citation:

    A First-in-Human Trial of MIV-150 and Zinc Acetate Co-Formulated in a Carrageenan Gel: Friedland, B,A., Hoesley, C.J., Plagianos, M., Hoskin, E., Zhang, S., Teleshova, N., …Creasy, G. (2016, July). Journal of Acquired Immune Deficiency Syndromes. 

    Authors:

    A First-in-Human Trial of MIV-150 and Zinc Acetate Co-Formulated in a Carrageenan Gel: Friedland, B,A., Hoesley, C.J., Plagianos, M., Hoskin, E., Zhang, S., Teleshova, N., …Creasy, G. 

    Health Risks(s):

    • HIV

    Product type(s):

    • Microbicide
    • MPTs

    Topic(s):

    • MPTs
    • Development
    • Trials

        URL of resource:

        http://journals.lww.com/jaids/Citation/2016/12150/First_in_Human_Trial_of_MIV_150_and_Zinc_Acetate.1.aspx

        Back to Resource Center